Si-bone, inc. reports financial results for the first quarter 2025 and updates 2025 guidance

First quarter 2025 financial highlights (all comparisons are to the prior year period) worldwide revenue of $47.3 million, representing growth of 24.9% u.s. revenue of $44.8 million, representing growth of 26.6% gross margin of 79.7%, representing an improvement of 80 basis points net loss of $6.5 million, representing an improvement of 40.0% positive adjusted ebitda of $0.5 million $144.4 million in cash and equivalents, with net cash usage in the quarter declining 31.7% to $5.6 million recent operational highlights (any comparisons are to the prior year period) over 1,400 active u.s. physicians with 300 physicians added in the quarter, representing 27.3% growth cms fy 2026 proposed hospital inpatient rule for new technology add-on payment (“ntap”) effective october 1, 2025, paying an additional amount up to $3,960 for procedures involving ifuse torq tnt santa clara, calif., may 05, 2025 (globe newswire) -- si-bone, inc. (nasdaq: sibn), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended march 31, 2025.
SIBN Ratings Summary
SIBN Quant Ranking